Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV. Kovtun YV, et al. Among authors: singh r. Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2. Cancer Res. 2010. PMID: 20197459
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ. Kellogg BA, et al. Among authors: singh r. Bioconjug Chem. 2011 Apr 20;22(4):717-27. doi: 10.1021/bc100480a. Epub 2011 Mar 22. Bioconjug Chem. 2011. PMID: 21425776
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing.
Widdison WC, Ponte JF, Coccia JA, Lanieri L, Setiady Y, Dong L, Skaletskaya A, Hong EE, Wu R, Qiu Q, Singh R, Salomon P, Fishkin N, Harris L, Maloney EK, Kovtun Y, Veale K, Wilhelm SD, Audette CA, Costoplus JA, Chari RV. Widdison WC, et al. Among authors: singh r. Bioconjug Chem. 2015 Nov 18;26(11):2261-78. doi: 10.1021/acs.bioconjchem.5b00430. Epub 2015 Sep 30. Bioconjug Chem. 2015. PMID: 26355774
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R, Setiady YY, Ponte J, Kovtun YV, Lai KC, Hong EE, Fishkin N, Dong L, Jones GE, Coccia JA, Lanieri L, Veale K, Costoplus JA, Skaletskaya A, Gabriel R, Salomon P, Wu R, Qiu Q, Erickson HK, Lambert JM, Chari RV, Widdison WC. Singh R, et al. Mol Cancer Ther. 2016 Jun;15(6):1311-20. doi: 10.1158/1535-7163.MCT-16-0021. Epub 2016 Mar 29. Mol Cancer Ther. 2016. PMID: 27197308
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.
Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV. Miller ML, et al. Among authors: singh r. Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23. Mol Cancer Ther. 2016. PMID: 27216304
19,477 results
You have reached the last available page of results. Please see the User Guide for more information.